PathGroup Acquires Pathology Consultants, Continuing Expansion Across the Southeastern United States

Combination enhances service offering for hospitals, physicians and patients of both companies

PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of Pathology Consultants, a leading provider of pathology services based in Greenville, S.C.

The combination of PathGroup and Pathology Consultants brings together two market leaders with deep histories of highly specialized pathology expertise, while adding PathGroup’s broader offering of clinical and molecular services for existing Pathology Consultants clients. Together, PathGroup and Pathology Consultants will provide physicians and patients across the Southeast with superior quality and service levels for their comprehensive testing needs.

“We welcome Pathology Consultants to the PathGroup family of more than 225 pathologists,” said Ben W. Davis, M.D., Chief Executive Officer of PathGroup. “Our companies share a 50-year legacy of proven commitment to our clients and patients, along with a culture of physician leadership. Together with the industry-leading health systems and practices of Pathology Consultants, we will continue providing highly specialized pathology expertise, as well as a broad range of clinical and molecular pathology services.”

“PathGroup and Pathology Consultants are complementary partners with shared values. Together we will provide the highest-quality pathology services to our clients and patients,” said David P. Schammel, M.D., Medical Director of Pathology Consultants. “We look forward to working with PathGroup to continue to exceed the expectations of our health systems and physician clients.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.